Results 21 to 30 of about 734,803 (234)
Optimization of multimeric human papillomavirus L2 vaccines. [PDF]
PLoS ONE, 2013 We sought to define the protective epitopes within the amino terminus of human papillomavirus (HPV) type 16 minor capsid protein L2. Passive transfer of mice with rabbit antisera to HPV16 L2 peptides 17-36, 32-51 and 65-81 provided significant protection
Subhashini Jagu +6 more
doaj +1 more source
Proceedings of Singapore Healthcare, 2017 Introduction: Although cervical cancer is the 10th most common cancer among females in Singapore, it is a vaccine-preventable cancer. Human papillomavirus vaccines combined with regular Pap (papillomavirus) smears have been shown to reduce the mortality ...
Sarah Woon Ching Lim +9 more
doaj +1 more source
New Perspectives in Therapeutic Vaccines for HPV: A Critical Review
Medicina, 2022 Human Papillomavirus is the main cause of cervical cancer, including squamous cell carcinoma of the oropharynx, anus, rectum, penis, vagina, and vulva.
Barbara Gardella +9 more
doaj +1 more source
Prophylactic human papillomavirus vaccines [PDF]
Journal of Clinical Investigation, 2006 Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the second most common cause of death from cancer among women worldwide. This Review examines prophylactic HPV subunit vaccines based on the ability of the viral L1 capsid protein to form virus-like particles (VLPs) that induce high levels of neutralizing antibodies ...
Douglas R, Lowy, John T, Schiller
openaire +2 more sources
Вопросы современной педиатрии, 2017 The article is devoted to the urgent problem of papillomavirus infection, the extremely high prevalence of which determines the key contribution to the structure of morbidity and mortality from oncological diseases. A chronic persistent course, resulting
Alexander A. Baranov +21 more
doaj +1 more source
Potential benefits of second-generation human papillomavirus vaccines. [PDF]
PLoS ONE, 2012 Current prophylactic vaccines against human papillomavirus (HPV) target two oncogenic types (16 and 18) that contribute to 70% of cervical cancer cases worldwide.
Sorapop Kiatpongsan +2 more
doaj +1 more source
Quadrivalent Human Papillomavirus Vaccine [PDF]
Clinical Infectious Diseases, 2007 The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldwide annually. Infection also causes precancerous lesions and genital warts. HPV types 16 and 18 cause approximately 70% of HPV-related cancers, and HPV types 6 and 11 cause approximately 90% of cases of ...
B. Gellin +3 more
openaire +2 more sources
SAGE Open, 2023 Studies on human papillomavirus (HPV) prevention education and its educational effects for elementary school students are necessary. This study aimed to examine the effects of human papillomavirus (HPV) prevention education on knowledge about cervical ...
Jeon Hee Kim +3 more
doaj +1 more source
Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. [PDF]
PLoS ONE, 2012 Human papillomavirus is known to be the major pathogen of cervical cancer. Here, we report the efficacy of a bivalent human papillomavirus type 16 and 18 DNA vaccine system following repeated dosing in mice and pigs using a recombinant baculovirus ...
Hee-Jung Lee +6 more
doaj +1 more source
Frontiers in Immunology, 2022 Licensed L1-VLP-based immunizations against high-risk mucosal human papillomavirus (HPV) types have been a great success in reducing anogenital cancers, although they are limited in their cross-protection against HPV types not covered by the vaccine ...
Melinda Ahmels +10 more
doaj +1 more source